A new approach to risk assessment for nanotechnology in healthcare includes the mapping of particles to risk profiles and the potential channels for the collection of relevant information. This relates assay type to processes probed and the recognition of the relevance of this to particle pathways. It is only by ensuring the sound regulation of this throughout the 'life cycle' of translational research and development, which we can ensure the true provenance of materials that we intend to use in the clinical environment.

No abstract